A5049113012- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Immune Cell Function and Interaction
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- Vascular Tumors and Angiosarcomas
- HER2/EGFR in Cancer Research
- Ferroptosis and cancer prognosis
- Cancer, Hypoxia, and Metabolism
- Gastric Cancer Management and Outcomes
- Multiple Myeloma Research and Treatments
- Immune cells in cancer
- Cancer Research and Treatments
- Metastasis and carcinoma case studies
- Pancreatic and Hepatic Oncology Research
- Healthcare Education and Workforce Issues
Yonsei University
2015-2025
Severance Hospital
2022-2025
University of Ulsan
2019-2023
Asan Medical Center
2023
Ulsan College
2023
Korea Advanced Institute of Science and Technology
2017-2020
Dae Hwa Pharm (South Korea)
2017
Patient-derived organoids (PDO) of lung cancer has been recently introduced, reflecting the genomic landscape cancer. However, clinical relevance advanced adenocarcinoma remains unknown. Here, we examined ability PDOs to predict responses targeted therapies in individual patients and identify effective anticancer for novel molecular targets.Eighty-four were established from with adenocarcinoma. Formalin-fixed, paraffin-embedded tumor specimens corresponding analyzed by whole-exome sequencing...
Trastuzumab-containing chemotherapy is the recommended first-line regimen for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer. We evaluated safety and efficacy of trastuzumab combined with ramucirumab paclitaxel as second-line treatment HER2-positive G/GEJ cancer.Patients cancer who progressed after trastuzumab-containing were enrolled from five centers in Republic Korea. Patients administered a 28-day cycle (once on days...
Background Oropharyngeal squamous cell carcinoma (OPSCC) induced by human papillomavirus (HPV-positive) is associated with better clinical outcomes than HPV-negative OPSCC. However, the benefits of immunotherapy in patients HPV-positive OPSCC remain unclear. Methods To identify cellular and molecular factors that limited HPV immunotherapy, we performed single-cell RNA (n=20) T-cell receptor sequencing (n=10) analyses tonsil or base tongue tumor biopsies prior to immunotherapy. Primary...
Atezolizumab plus bevacizumab (Ate/Bev) demonstrated promising efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) the phase III IMbrave150 trial. However, Child-Pugh B HCC were excluded abovementioned prospective Therefore, we aimed to investigate of Ate/Bev HCC.This multicenter retrospective study included 36 who received at four cancer referral centers between May 2020 August 2021. Comparative analyses performed an independent cohort A from same registry (n =...
Background Reinvigoration of T-cell exhaustion with antibodies has shown promising efficacy in patients non-small-cell lung cancer (NSCLC). However, the characteristics regard to tumor-infiltrating lymphocytes (TILs) are poorly elucidated NSCLC. Here, we investigated status TILs NSCLC at intraindividual and interindividual levels. Methods We obtained paired peripheral blood, normal adjacent tissues, peritumoral tumor tissues from 96 patients. Features were analyzed by flow cytometry. T cells...
Abstract Background Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have been established as a standard treatment for hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer (ABC); however, predictive biomarkers with translational relevance not yet elucidated. Methods Data from postmenopausal women who received the CDK4/6 inhibitor palbociclib letrozole HR-positive, HER2-negative ABC tertiary referral centers were analyzed ( N = 221;...
Evidence on whether prior antibiotic (pATB) administration modulates outcomes of programmed cell death protein-1 (PD-1) inhibitors in advanced gastric cancer (AGC) is scarce. In this study, we find that pATB consistently associated with poor progression-free survival (PFS) and overall (OS) multiple cohorts consisting patients AGC treated PD-1 inhibitors. contrast, does not affect among irinotecan. Multivariable analysis the confirms independently predicts worse PFS OS. Administration pATBs...
Clinical implications of neoadjuvant immunotherapy in patients with locally advanced but resectable head and neck squamous cell carcinoma (HNSCC) remain largely unexplored.
ABSTRACT Background This study analyzed the clinical features of patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), who developed progressive disease (PD) after immune checkpoint inhibitor (ICI) therapy. Methods We retrospectively 256 R/M HNSCC treated ICIs at 11 medical centers. Associations between treatment outcomes―best response, overall survival, progression‐free survival―and various factors were analyzed. Results The objective response rate was...
588 Background: Although histologically defined subtypes exist, renal cell carcinoma (RCC) is a heterogenous disease, resulting in various treatment outcomes and prognosis. Here, we conducted comprehensive profiling of RCC with histopathologic, proteomic, phosphoproteomic, genomic, transcriptomic analyses on tumor paired adjacent normal tissues from 113 patients. Methods: Tumor matched were subjected to proteomic phosphoproteomic analysis (N=113), whole exome sequencing (N=74), (N=70)....
Abstract Head and neck squamous cell carcinoma (HNSCC) presents a significant therapeutic challenge because of the limited effectiveness current treatments including immunotherapy chemotherapy. This study investigated potential novel combination therapy using allogeneic natural killer (NK) cells cetuximab, an anti-epidermal growth factor receptor monoclonal antibody, to enhance anti-tumor efficacy in HNSCC. Allogeneic NK were tested against HNSCC vitro NOG (NOD/Shi-scid/IL-2Rγ null)...
Abstract Background: Liquid biopsy offers a minimally invasive alternative to tissue biopsy, enabling therapeutic monitoring, precision medicine-based treatment decisions, and detection of tumor heterogeneity. Circulating cell (CTC) analysis is promising biomarker for monitoring response stratifying prognosis in EGFR-mutant non-small lung cancer (NSCLC). Meanwhile, CTCs peripheral blood challenging due their rarity the limitations both marker-dependent marker-independent isolation...
Inter-tumoral heterogeneity at the differential lesion level raises possibility of distinct organ-specific responses to immune checkpoint inhibitors (ICIs). We aimed comprehensively examine clinicopathological factors predict and assess efficacy nivolumab, programmed cell death protein 1 (PD-1) blockade an individual tumor site-specific in patients with advanced hepatocellular carcinoma (aHCC).We enrolled 261 aHCC treated nivolumab between 2012 2018. Eighty-one were collected analyzed. The...
Abstract Background Dysregulation of iron metabolism is implicated in malignant transformation, cancer progression, and therapeutic resistance. Here, we demonstrate that regulatory protein 2 (IRP2) preferentially regulates promotes tumor growth colorectal (CRC). Methods IRP2 knockdown knockout cells were generated using RNA interference clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 methodologies, respectively. Cell viability was evaluated both CCK-8 assay cell...
Abstract Background The purpose of this study was to investigate the efficacy and safety vinorelbine plus cisplatin chemotherapy in patients with recurrent and/or metastatic salivary gland cancer head neck. Methods In single‐arm phase II study, were treated i.v. (25 mg/m 2 ) on days 1 8 (80 day every 3 weeks for 4 or 6 cycles. primary endpoint objective response rate. Progression‐free survival (PFS), overall (OS), adverse events also assessed. Results Between September 2008 November 2014, 40...
Abstract Background There are large variations in prognosis among hepatocellular carcinoma (HCC) patients undergoing radiofrequency ablation (RFA). However, current staging or scoring systems hardly discriminate the outcome of HCC treated with RFA. Methods A total 757 treatment‐naïve RFA (derivation cohort) were analyzed to establish a nomogram for disease‐free survival (DFS) based on Cox proportional hazard regression model. Accuracy was assessed and compared conventional systems....
Doxorubicin/cyclophosphamide followed by docetaxel chemotherapy (AC-D) is an intermediate risk factor (incidence of 10%-20%) for febrile neutropenia (FN) in breast cancer. However, the reported incidence FN while using this regimen was obtained mostly from Western cancer patients, with little data available Asian patients. This study aimed to assess Korean patients and describe clinical variables related FN.From September 2010 February 2013, Yonsei Cancer Center registry who received...
This study was designed to prospectively examine whether peptide nucleic acid clamping-assisted fluorescence melting curve analysis (PANAMutyper™) is feasible for the detection of activating and acquired resistant epidermal growth factor receptor (EGFR) mutation in plasma. Patients with non-small cell lung cancer harboring EGFR mutations who were scheduled undergo EGFR-tyrosine kinase inhibitors (EGFR-TKIs) enrolled between September 2011 March 2015. A total 102 patients EGFR-mutated...
Predictive markers for treatment response and survival outcome have not been identified in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemoimmunotherapy. We aimed to evaluate whether imaging biomarkers of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) routinely assessed clinico-laboratory values were associated clinical outcomes NSCLC pembrolizumab plus platinum-doublet chemotherapy as a first-line treatment.We...